<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-26140" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Ofloxacin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Graham</surname>
            <given-names>Derrick B.</given-names>
          </name>
          <aff>TTUHSC SOM</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tripp</surname>
            <given-names>Jayson</given-names>
          </name>
          <aff>CUSOM/Cape Fear Valley Health Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Derrick Graham declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jayson Tripp declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-26140.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Ofloxacin is an antimicrobial drug in the fluoroquinolone family that effectively treats various bacterial infections. It received FDA approval in 1990. Ofloxacin is a medication in the fluoroquinolone class used to treat multiple gram-positive and gram-negative bacterial infections. This activity reviews the indications, mechanism of action, administration, adverse effects, contraindications, and other critical characteristics of ofloxacin that are pertinent for healthcare team members in managing patients with pneumonia, conjunctivitis, and ear infections, urinary tract infections, and other such infections.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of ofloxacin.</p></list-item><list-item><p>Describe the adverse effects and contraindications of ofloxacin.</p></list-item><list-item><p>Review the appropriate monitoring for ofloxacin.</p></list-item><list-item><p>Explain interprofessional team strategies for improving care coordination and communication to advance ofloxacin administration and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26140&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26140">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-26140.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Ofloxacin is an&#x000a0;antimicrobial drug&#x000a0;in the&#x000a0;fluoroquinolone family&#x000a0;that effectively treats various&#x000a0;bacterial infections.&#x000a0;It received FDA approval in&#x000a0;1990 as a&#x000a0;"1C" drug,&#x000a0;categorizing&#x000a0;it as&#x000a0;a&#x000a0;new molecular entity&#x000a0;offering&#x000a0;little or no therapeutic&#x000a0;advantage&#x000a0;over&#x000a0;existing therapies,&#x000a0;namely,&#x000a0;ciprofloxacin.&#x000a0;Yet,&#x000a0;despite&#x000a0;its&#x000a0;little&#x000a0;therapeutic&#x000a0;benefit, ofloxacin&#x000a0;earned support for its&#x000a0;improved oral bioavailability,&#x000a0;longer half-life, and expanded&#x000a0;applications to&#x000a0;certain sexually transmitted&#x000a0;infections compared to its counterpart, ciprofloxacin.<bold>&#x000a0;</bold><italic toggle="yes">Pseudomonas aeruginosa&#x000a0;</italic>may develop resistance rapidly during treatment with ofloxacin. Hence, Culture and susceptibility testing performed during therapy can provide information about the therapeutic effect of the antimicrobial agent and the possible emergence of bacterial resistance.&#x000a0;Fluoroquinolones, including ofloxacin,&#x000a0;are&#x000a0;associated with serious adverse reactions; hence it is prudent to reserve ofloxacin where there are no alternative treatment options.</p>
        <p>The following are FDA-approved indications for ofloxacin use according to the manufacturer label.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Otitis Externa in pediatric patients six months and older and adults from infection with&#x000a0;<italic toggle="yes">Escherichia&#x000a0;coli,&#x000a0;Pseudomonas&#x000a0;aeruginosa,&#x000a0;</italic>or&#x000a0;<italic toggle="yes">Staphylococcus aureus&#x000a0;</italic>(otic solution, 0.3%)</p>
          </list-item>
          <list-item>
            <p>Chronic Suppurative Otitis Media in patients 12 years and above with perforated tympanic membranes because of&#x000a0;<italic toggle="yes">Pseudomonas aeruginosa,&#x000a0;Proteus mirabilis, </italic>or&#x000a0;<italic toggle="yes">Staphylococcus aureus </italic>(otic solution, 0.3%)</p>
          </list-item>
          <list-item>
            <p>Acute Otitis Media in pediatric patients one year age with tympanostomy tubes due to&#x000a0;<italic toggle="yes">Moraxella catarrhalis, Haemophilus&#x000a0;influenzae, Pseudomonas&#x000a0;aeruginosa&#x000a0;Staphylococcus aureus,&#x000a0;</italic>or&#x000a0;<italic toggle="yes">Streptococcus&#x000a0;pneumonia&#x000a0;</italic>(otic solution, 0.3%)</p>
          </list-item>
          <list-item>
            <p>Conjunctivitis due to&#x000a0;<italic toggle="yes">Enterobacter&#x000a0;cloacae,&#x000a0;Staphylococcus aureus, Staphylococcus epidermidis, Haemophilus&#x000a0;influenzae, Streptococcus pneumoniae, Proteus mirabilis,&#x000a0;</italic>or&#x000a0;<italic toggle="yes">Pseudomonas aeruginosa </italic>(ophthalmic solution 0.3%)</p>
          </list-item>
          <list-item>
            <p>Corneal ulcers due to&#x000a0;infection with&#x000a0;<italic toggle="yes">Staphylococcus&#x000a0;aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Enterobacter cloacae,&#x000a0;Haemophilus&#x000a0;influenzae, Proteus mirabilis,&#x000a0;Pseudomonas&#x000a0;aeruginosa, Serratia marcescens,&#x000a0;</italic>or&#x000a0;<italic toggle="yes">Cutibacterium acnes.&#x000a0;</italic>(ophthalmic solution 0.3%)</p>
          </list-item>
          <list-item>
            <p>Acute bacterial exacerbations of chronic bronchitis resulting from&#x000a0;<italic toggle="yes">Haemophilus&#x000a0;influenzae or Streptococcus pneumoniae</italic></p>
          </list-item>
          <list-item>
            <p>Community-acquired pneumonia due to&#x000a0;<italic toggle="yes">Haemophilus&#x000a0;influenzae or Streptococcus pneumoniae</italic></p>
          </list-item>
          <list-item>
            <p>Uncomplicated skin and skin structure infection due to&#x000a0;<italic toggle="yes">methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis</italic></p>
          </list-item>
          <list-item>
            <p>Acute, uncomplicated urethral and cervical gonorrhea from&#x000a0;<italic toggle="yes">Neisseria gonorrhoeae</italic>&#x000a0;infection</p>
          </list-item>
          <list-item>
            <p>Nongonococcal urethritis and cervicitis due to&#x000a0;<italic toggle="yes">Chlamydia trachomatis</italic></p>
          </list-item>
          <list-item>
            <p>Mixed infections of the urethra and cervix with&#x000a0;<italic toggle="yes">Chlamydia trachomatis&#x000a0;</italic>or&#x000a0;<italic toggle="yes">Neisseria gonorrhoeae</italic></p>
          </list-item>
          <list-item>
            <p>Acute pelvic inflammatory disease (includes severe infection) due to&#x000a0;<italic toggle="yes">Chlamydia trachomatis&#x000a0;</italic>or<italic toggle="yes">&#x000a0;Neisseria gonorrhoeae</italic></p>
          </list-item>
          <list-item>
            <p>Uncomplicated cystitis as a result of&#x000a0;<italic toggle="yes">Citrobacter&#x000a0;diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa</italic></p>
          </list-item>
          <list-item>
            <p>Complicated urinary tract infections from infection with&#x000a0;<italic toggle="yes">Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter&#x000a0;diversus,&#x000a0;</italic>or<italic toggle="yes">&#x000a0;Pseudomonas aeruginosa</italic></p>
          </list-item>
          <list-item>
            <p>Prostatitis resulting from&#x000a0;<italic toggle="yes">Escherichia coli</italic></p>
          </list-item>
        </list>
        <p>The following are the&#x000a0;non-FDA-approved use of ofloxacin.</p>
        <list list-type="bullet">
          <list-item>
            <p>Leprosy<xref ref-type="bibr" rid="article-26140.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>Epididymitis<xref ref-type="bibr" rid="article-26140.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Spontaneous bacterial peritonitis<xref ref-type="bibr" rid="article-26140.r3">[3]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Traveler's&#x000a0;diarrhea(TD)- According to the American Society for Microbiology,&#x000a0;fluoroquinolones should no longer be considered the drugs of choice for the prevention or treatment of TD for travelers traveling to India and Africa due to the emergence of resistance to Fluoroquinolones.<xref ref-type="bibr" rid="article-26140.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Enteric fever-&#x000a0;Fluoroquinolones are used for empiric treatment of enteric fever in adults and are regarded as the treatment of choice for fluoroquinolone-susceptible infections. However, in the United States, &#x02265;90% of <italic toggle="yes">Typh</italic>i and <italic toggle="yes">Paratyphi A</italic> infections in travelers to South Asia&#x000a0;are fluoroquinolone-nonsusceptible, suggesting that treatment failures may occur among patients treated empirically with fluoroquinolones. Hence, azithromycin and ceftriaxone are increasingly used to treat enteric fever.<xref ref-type="bibr" rid="article-26140.r5">[5]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26140.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>As&#x000a0;with other second-generation fluoroquinolone drugs, ofloxacin&#x000a0;is a&#x000a0;broad-spectrum&#x000a0;antimicrobial that exhibits&#x000a0;a bactericidal effect.&#x000a0;It works by binding to and inhibiting bacterial&#x000a0;topoisomerase II (DNA gyrase),&#x000a0;an enzyme that&#x000a0;relaxes&#x000a0;supercoiled DNA,&#x000a0;and topoisomerase IV,&#x000a0;an enzyme that&#x000a0;separates linked daughter chromosomes&#x000a0;following replication. These inhibitory effects interrupt&#x000a0;DNA replication, transcription, and repair, thereby preventing cell division in bacterial cells.<xref ref-type="bibr" rid="article-26140.r6">[6]</xref>&#x000a0;In addition, fluoroquinolones are bactericidal and are concentrated intracellularly, resulting in rapid intracellular killing.&#x000a0;</p>
        <p>
<bold>Mechanism of Resistance</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Chromosome-encoded mutation in DNA gyrase</p>
          </list-item>
          <list-item>
            <p>Plasmid-mediated resistance, efflux pumps<xref ref-type="bibr" rid="article-26140.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;After oral administration, the bioavailability of the ofloxacin tablet is approximately 98%. Maximum serum concentrations (Cmax) are achieved one to two hours after an oral dose.<xref ref-type="bibr" rid="article-26140.r8">[8]</xref></p>
        <p><bold>Distribution:&#x000a0;</bold>In vitro, approximately 32% of the drug in plasma is protein bound. After oral administration of recommended therapeutic doses, ofloxacin has been detected in lung tissue, blister fluid, cervix, ovary, prostatic fluid, prostatic tissue, sputum, and skin.</p>
        <p><bold>Metabolism:&#x000a0;</bold>Ofloxacin has a pyridobenzoxazine ring that appears to decrease the extent of parent compound metabolism.</p>
        <p><bold>Excretion:</bold>&#x000a0;Ofloxacin has biphasic elimination. Between 65% to 80% of an administered oral dose of ofloxacin is excreted unchanged via the kidneys within 48 hours of dosing. In addition, studies indicate that 4% to 8% percent of an ofloxacin dose is excreted in the feces indicating a small degree of biliary excretion of ofloxacin.</p>
      </sec>
      <sec id="article-26140.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Dosage Formulations</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Oral:Ofloxacin tablets 200&#x000a0;mg, 300 mg,400 mg</p>
          </list-item>
          <list-item>
            <p>Topical: Ofloxacin Ophthalmic Solution USP 0.3% is used</p>
          </list-item>
          <list-item>
            <p>Topical: Ofloxacin Otic Solution USP, 0.3%</p>
          </list-item>
        </list>
        <p>General&#x000a0;infections&#x000a0;receive oral or intravenous ofloxacin. In severe infection, intravenous administration is preferable as it allows higher dosing, leading to higher drug concentrations, ultimately increasing clinical cure rates.<xref ref-type="bibr" rid="article-26140.r9">[9]</xref>&#x000a0;Topical preparations exist for specific cases. For otitis externa and otitis media, patients have treatment with an ofloxacin&#x000a0;otic&#x000a0;drop solution. Topical ofloxacin penetrates the tympanic membrane, achieving similar middle ear concentrations through topical or systemic administration.<xref ref-type="bibr" rid="article-26140.r10">[10]</xref>&#x000a0;Patients can receive an ofloxacin ophthalmic drop solution for bacterial conjunctivitis and corneal ulcers. An animal study demonstrated that topical ofloxacin permeates the cornea, achieving therapeutic concentrations in the anterior and posterior chambers of the eye while sparing the retina from any toxic effects.<xref ref-type="bibr" rid="article-26140.r11">[11]</xref></p>
        <p>
<bold>Use in Specific Patient Population</bold>
</p>
        <p><bold>Renal Impairment: </bold>Clearance of ofloxacin is reduced in patients with impaired renal function (creatinine clearance rate &#x02264;50 mL/min), and dosage adjustment is required.</p>
        <p><bold>Hepatic Impairment: </bold>No dosage adjustments are&#x000a0;provided in the manufacturer's labeling; use caution. Administer ofloxacin with caution in patients with hepatic insufficiency and /or impairment.</p>
        <p><bold>Pregnancy Considerations:&#x000a0;</bold>Contraindicated during pregnancy or&#x000a0;breastfeeding and in children &#x0003c; 18 years old&#x000a0;due to possible damage to the cartilage. Based on available data, an increased risk of teratogenic effects has not been observed following ofloxacin use during pregnancy, and literature is conflicting regarding their safety in humans.&#x000a0;Ofloxacin should be used for pregnant women only if the potential benefit outweighs the potential risk to the fetus. Alternative antibiotics should be preferred till more safety data is available. (FDA Pregnancy Category C).<xref ref-type="bibr" rid="article-26140.r12">[12]</xref></p>
        <p><bold>Breastfeeding Considerations: </bold>Ofloxacin is distributed in breastmilk at low levels. Fluoroquinolones have traditionally not been used in infants because of concern about adverse effects on the infants' developing joints. However, recent studies indicate little risk. The calcium in milk might prevent the absorption of small amounts of fluoroquinolones. Insufficient data exist to prove or disprove this assertion. Developmental problems have been reported in two infants exposed to ofloxacin in breastmilk, but their mothers were also exposed to several drugs during the peripartum period; hence the adverse drug reaction cannot necessarily be attributed to ofloxacin. The use of ofloxacin is permitted in nursing mothers with monitoring of the infant for potential effects on the gut flora, such as diarrhea or candidiasis (thrush, diaper rash).</p>
        <p>Avoiding breastfeeding for 4 to 6 hours after a dose should decrease the infant's exposure to ofloxacin in breastmilk. Maternal use of an ear drop or eye drop that contains ofloxacin presents a negligible risk for the nursing infant. To substantially decrease the amount of drug that reaches the breastmilk after eye drops, apply pressure over the tear duct by the corner of the eye for one minute and remove the leftover solution with an absorbent tissue. A literature&#x000a0;search reveals that ofloxacin was used to treat two pregnant women with MDR tuberculosis. Subsequently, the children had normal development except for a mild speech delay and hyperactivity in the other.<xref ref-type="bibr" rid="article-26140.r13">[13]</xref></p>
      </sec>
      <sec id="article-26140.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p><bold>Tendinopathy</bold>: The most characteristic&#x000a0;adverse effect of ofloxacin treatment and other fluoroquinolone treatments is tendinopathy, typically presenting&#x000a0;as pain or swelling along a tendon&#x02019;s path. Such injury has been observed both during drug administration and several months after. In addition, there is a particularly high risk of tendon rupture in patients receiving corticosteroid therapy or engaging in strenuous physical activity with concurrent ofloxacin administration. This injury primarily affects the Achilles tendon and necessitates surgical repair.&#x000a0;&#x000a0;</p>
        <p><bold>Central Nervous System ADRs</bold>:&#x000a0;It is also possible for ofloxacin treatment to cause increased intracranial pressure and psychosis.<xref ref-type="bibr" rid="article-26140.r14">[14]</xref> As ofloxacin may stimulate the central nervous system, neurological effects such as&#x000a0;seizures, lightheadedness, hallucinations, restlessness, tremors, anxiety, depression, confusion, difficulty sleeping, nightmares, paranoia, or suicidal thoughts or acts occur. These effects may develop after as little as one dose and call for immediate termination of treatment. Caution is necessary when considering therapy for patients with preexisting conditions or risk factors predisposing to seizures or other CNS effects.&#x000a0;</p>
        <p><bold>Hypersensitivity reactions</bold>:&#x000a0;Hypersensitivity reactions are another adverse effect occasionally observed with ofloxacin treatment, most frequently following the initial dose. This Type I hypersensitivity reaction results from some patients performing serum IgE against ofloxacin.&#x000a0;Reported signs of a hypersensitivity reaction include seizure, cardiovascular collapse, shock, loss of consciousness,&#x000a0;airway obstruction, dyspnea,&#x000a0;tingling, angioedema, urticaria, itching, and other allergic skin manifestations.&#x000a0;</p>
        <p>On a rare occasion and following multiple doses, other serious and sometimes fatal hypersensitivity-associated events have been observed, involving fever, rash, severe dermatologic reactions, vasculitis, serum sickness, arthralgia, myalgia, allergic pneumonitis, interstitial nephritis, acute renal insufficiency or failure, acute hepatic necrosis or failure, hepatitis, jaundice, hemolytic or aplastic anemia, thrombocytopenia, leukopenia, agranulocytosis, pancytopenia, and other hematologic disorders. As with other hypersensitivity reactions, the earliest indication of these clinical manifestations calls for immediate treatment discontinuation.<xref ref-type="bibr" rid="article-26140.r15">[15]</xref></p>
        <p><bold>Peripheral Neuropathy</bold>: Though uncommon, ofloxacin treatment has also led to reports of peripheral neuropathy, as manifested by pain, burning, tingling, numbness, weakness, and altered sensation.&#x000a0;Exacerbation of muscle weakness in a patient with myasthenia gravis is a dangerous possibility.&#x000a0;The earliest indication of these clinical manifestations calls for immediate discontinuation of treatment.&#x000a0;</p>
        <p><bold>Hepatotoxicity:</bold> The severity of the ofloxacin-induced liver injury ranges from mild and transient serum enzyme elevations to self-limited jaundice to acute liver failure. Recovery is usually rapid (2 to 8 weeks) after stopping the medication. Cross-reactivity between different fluoroquinolones has not been well defined but is presumed based on the similarity of injury and clinical patterns. Thus, patients should avoid further exposure to fluoroquinolones, particularly levofloxacin, the isomer of ofloxacin.<xref ref-type="bibr" rid="article-26140.r16">[16]</xref></p>
        <p><bold>Dysglycemia</bold>: Fluoroquinolones have been associated with symptomatic hyperglycemia and hypoglycemia, usually in diabetic patients getting concomitant treatment with an oral hypoglycemic agent or with insulin. In these patients, meticulous monitoring of blood glucose is recommended.<xref ref-type="bibr" rid="article-26140.r17">[17]</xref></p>
        <p><bold>Aortic Aneurysm:</bold>&#x000a0;Other rare and serious adverse effects include prolonging the QTc interval and aortic aneurysms.<xref ref-type="bibr" rid="article-26140.r18">[18]</xref></p>
      </sec>
      <sec id="article-26140.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Ofloxacin use is contraindicated in patients with a history of quinolone-associated hypersensitivity reactions, myasthenia gravis, and prolonged QTc interval. Unless there is no other option, it is also contraindicated in patients with a history of or at increased risk for aortic aneurysm,&#x000a0;Marfan&#x000a0;syndrome, or Ehlers-Danlos syndrome.</p>
        <p>
<bold>US Boxed Warning</bold>
</p>
        <p>Fluoroquinolones, including ofloxacin, have been associated with potentially irreversible serious adverse reactions that have occurred together, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Tendinitis and tendon rupture</p>
          </list-item>
          <list-item>
            <p>Peripheral neuropathy</p>
          </list-item>
          <list-item>
            <p>Central nervous system effects&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Exacerbation of Myasthenia Gravis<xref ref-type="bibr" rid="article-26140.r19">[19]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26140.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Ofloxacin is regarded as a safe drug with a considerable safety margin.<xref ref-type="bibr" rid="article-26140.r20">[20]</xref><xref ref-type="bibr" rid="article-26140.r21">[21]</xref>&#x000a0;Tests are&#x000a0;recommended for patients with an increased risk of adverse effects or in cases with a long treatment course.</p>
        <p>Monitoring parameters include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Serum&#x000a0;plasma creatinine concentrations</p>
          </list-item>
          <list-item>
            <p>Liver function tests</p>
          </list-item>
          <list-item>
            <p>Serum glucose levels in diabetic patients<xref ref-type="bibr" rid="article-26140.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>EKG monitoring for ofloxacin-induced&#x000a0;QTc prolongation, although the risk is low for ofloxacin compared to other fluoroquinolones.<xref ref-type="bibr" rid="article-26140.r22">[22]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26140.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Information on toxicity with ofloxacin is limited. One case report of accidental overdosage has been described in which an adult female received 3 grams of ofloxacin intravenously over 45 minutes. The patient developed dizziness, hot and cold flushes, drowsiness, nausea, slurring of speech, and mild to moderate disorientation during the infusion. Laboratory testing detected no clinically significant changes in routine parameters in this patient.&#x000a0;</p>
        <p>In overdose cases, gastric lavage and sufficient hydration are the recommended interventions. Unfortunately, no antidotes exist, and dialysis treatments are ineffective in reversing toxicity.<xref ref-type="bibr" rid="article-26140.r21">[21]</xref>&#x000a0;Activated charcoal may decrease ofloxacin absorption and reduce the likelihood of systemic toxicity if orally ingested.<xref ref-type="bibr" rid="article-26140.r23">[23]</xref></p>
      </sec>
      <sec id="article-26140.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Many severe adverse effects of ofloxacin treatment are avoidable by supporting patients with diverse interprofessional teams of healthcare providers. A nurse or&#x000a0;clinician (MD, DO, NP, or PA) taking the patient's history may identify patients at high risk due to previous hypersensitivity reactions, tendon disorders, cardiovascular disorders,&#x000a0;Marfan&#x000a0;syndrome, Ehlers-Danlos syndrome, or risk factors that lower the seizure threshold. Pharmacists may notice red flags for patients already taking corticosteroids, antiarrhythmics, or CNS medications whose adverse effects would be compounded by ofloxacin treatment.</p>
        <p>In these cases, the patients benefit from proactive interprofessional teams capable of working together to devise alternative drug treatment plans or ensure proper monitoring to ensure successful treatment and avoid adverse effects. The pharmacist should assist the team by verifying dosing, and in severe cases, an infectious disease board-certified pharmacist can provide antibiogram data to direct agent selection. Nursing can monitor for adverse events and treatment effectiveness. All interprofessional team members must document any changes in the patient's status immediately in the permanent health record, so all team members have access to the same patient data&#x000a0;and reach out to other team members as appropriate so therapeutic changes can occur, if necessary. This type of interprofessional team paradigm enhances positive results while minimizing adverse effects. [Level 5]</p>
      </sec>
      <sec id="article-26140.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26140&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26140">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/26140/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=26140">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-26140.s11">
        <title>References</title>
        <ref id="article-26140.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Girdhar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Girdhar</surname>
                <given-names>BK</given-names>
              </name>
            </person-group>
            <article-title>A randomized controlled trial to compare cure and relapse rate of paucibacillary multidrug therapy with monthly rifampicin, ofloxacin, and minocycline among paucibacillary leprosy patients in Agra District, India.</article-title>
            <source>Indian J Dermatol Venereol Leprol</source>
            <year>2015</year>
            <season>Jul-Aug</season>
            <volume>81</volume>
            <issue>4</issue>
            <fpage>356</fpage>
            <page-range>356-62</page-range>
            <pub-id pub-id-type="pmid">26144850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26140.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vieler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jantos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schmidts</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Weidner</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Schiefer</surname>
                <given-names>HG</given-names>
              </name>
            </person-group>
            <article-title>Comparative efficacies of ofloxacin, cefotaxime, and doxycycline for treatment of experimental epididymitis due to Escherichia coli in rats.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>1993</year>
            <month>Apr</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>846</fpage>
            <page-range>846-50</page-range>
            <pub-id pub-id-type="pmid">8494382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26140.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ta&#x0015f;kiran</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Colako&#x0011f;lu</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>S&#x000f6;zmen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Unsal</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aslan</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Buyra&#x000e7;</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Comparison of cefotaxime and ofloxacin in treatment of spontaneous bacterial peritonitis.</article-title>
            <source>Turk J Gastroenterol</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <page-range>34-8</page-range>
            <pub-id pub-id-type="pmid">15264119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26140.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guiral</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gon&#x000e7;alves Quiles</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Moreno-Morales</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Alejo-Cancho</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Salvador</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Alvarez-Martinez</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Marco</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vila</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Emergence of Resistance to Quinolones and &#x003b2;-Lactam Antibiotics in Enteroaggregative and Enterotoxigenic <italic>Escherichia coli</italic> Causing Traveler's Diarrhea.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>63</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">30478165</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26140.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Basnyat</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Qamar</surname>
                <given-names>FN</given-names>
              </name>
              <name>
                <surname>Rupali</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Parry</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Enteric fever.</article-title>
            <source>BMJ</source>
            <year>2021</year>
            <month>Feb</month>
            <day>26</day>
            <volume>372</volume>
            <fpage>n437</fpage>
            <pub-id pub-id-type="pmid">33637488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26140.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levine</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hiasa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Marians</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities.</article-title>
            <source>Biochim Biophys Acta</source>
            <year>1998</year>
            <month>Oct</month>
            <day>01</day>
            <volume>1400</volume>
            <issue>1-3</issue>
            <fpage>29</fpage>
            <page-range>29-43</page-range>
            <pub-id pub-id-type="pmid">9748489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26140.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hooper</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Jacoby</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of drug resistance: quinolone resistance.</article-title>
            <source>Ann N Y Acad Sci</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>1354</volume>
            <issue>1</issue>
            <fpage>12</fpage>
            <page-range>12-31</page-range>
            <pub-id pub-id-type="pmid">26190223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26140.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pitman</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Hoang</surname>
                <given-names>UTP</given-names>
              </name>
              <name>
                <surname>Wi</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Alsheikh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hiner</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Percival</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Revisiting Oral Fluoroquinolone and Multivalent Cation Drug-Drug Interactions: Are They Still Relevant?</article-title>
            <source>Antibiotics (Basel)</source>
            <year>2019</year>
            <month>Jul</month>
            <day>31</day>
            <volume>8</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">31370320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26140.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Modai</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>High-dose intravenous fluoroquinolones in the treatment of severe infections.</article-title>
            <source>J Chemother</source>
            <year>1999</year>
            <month>Dec</month>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>478</fpage>
            <page-range>478-85</page-range>
            <pub-id pub-id-type="pmid">10678789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26140.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koulich</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Roland</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Pawlowski</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>Comparison of systemic and otic administration of ofloxacin.</article-title>
            <source>Laryngoscope</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>120</volume>
            <issue>10</issue>
            <fpage>2083</fpage>
            <page-range>2083-8</page-range>
            <pub-id pub-id-type="pmid">20830758</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26140.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Raizman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Callina</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lahav</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Retinal safety of oral and topical ofloxacin in rabbits.</article-title>
            <source>J Ocul Pharmacol Ther</source>
            <year>1997</year>
            <month>Aug</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>369</fpage>
            <page-range>369-79</page-range>
            <pub-id pub-id-type="pmid">9261772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26140.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yefet</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chazan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Salim</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Romano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nachum</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>The safety of quinolones and fluoroquinolones in pregnancy: a meta-analysis.</article-title>
            <source>BJOG</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>125</volume>
            <issue>9</issue>
            <fpage>1069</fpage>
            <page-range>1069-1076</page-range>
            <pub-id pub-id-type="pmid">29319210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26140.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <chapter-title>Ofloxacin</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>2</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000114</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26140.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zaudig</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>von Bose</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Ofloxacin-induced psychosis.</article-title>
            <source>Br J Psychiatry</source>
            <year>1987</year>
            <month>Oct</month>
            <volume>151</volume>
            <fpage>563</fpage>
            <page-range>563-4</page-range>
            <pub-id pub-id-type="pmid">3482162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26140.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nam</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>Immunologic evaluation of ofloxacin hypersensitivity.</article-title>
            <source>Allergy Asthma Immunol Res</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>367</fpage>
            <page-range>367-9</page-range>
            <pub-id pub-id-type="pmid">23115735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26140.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <chapter-title>Ofloxacin</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>3</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">31644229</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26140.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El Ghandour</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Azar</surname>
                <given-names>ST</given-names>
              </name>
            </person-group>
            <article-title>Dysglycemia associated with quinolones.</article-title>
            <source>Prim Care Diabetes</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>168</fpage>
            <page-range>168-71</page-range>
            <pub-id pub-id-type="pmid">25466161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26140.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rawla</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>El Helou</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Vellipuram</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Fluoroquinolones and the Risk of Aortic Aneurysm or Aortic Dissection: A Systematic Review and Meta-Analysis.</article-title>
            <source>Cardiovasc Hematol Agents Med Chem</source>
            <year>2019</year>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-10</page-range>
            <pub-id pub-id-type="pmid">30947680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26140.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Sorbello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boucher</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review.</article-title>
            <source>Drug Saf</source>
            <year>2011</year>
            <month>Oct</month>
            <day>01</day>
            <volume>34</volume>
            <issue>10</issue>
            <fpage>839</fpage>
            <page-range>839-47</page-range>
            <pub-id pub-id-type="pmid">21879778</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26140.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tack</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>The safety profile of ofloxacin.</article-title>
            <source>Am J Med</source>
            <year>1989</year>
            <month>Dec</month>
            <day>29</day>
            <volume>87</volume>
            <issue>6C</issue>
            <fpage>78S</fpage>
            <page-range>78S-81S</page-range>
            <pub-id pub-id-type="pmid">2690623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26140.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Todd</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Faulds</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.</article-title>
            <source>Drugs</source>
            <year>1991</year>
            <month>Nov</month>
            <volume>42</volume>
            <issue>5</issue>
            <fpage>825</fpage>
            <page-range>825-76</page-range>
            <pub-id pub-id-type="pmid">1723377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26140.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cho</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>Association of oral ciprofloxacin, levofloxacin, ofloxacin and moxifloxacin with the risk of serious ventricular arrhythmia: a nationwide cohort study in Korea.</article-title>
            <source>BMJ Open</source>
            <year>2018</year>
            <month>Sep</month>
            <day>28</day>
            <volume>8</volume>
            <issue>9</issue>
            <fpage>e020974</fpage>
            <pub-id pub-id-type="pmid">30269062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26140.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stass</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kubitza</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>M&#x000f6;ller</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Delesen</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2005</year>
            <month>May</month>
            <volume>59</volume>
            <issue>5</issue>
            <fpage>536</fpage>
            <page-range>536-41</page-range>
            <pub-id pub-id-type="pmid">15842551</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
